• Explore /
  • Poster
  • / Final clinical outcome and biomarker analysis of sintilimab plus a bevacizumab biosimilar (IBI305) for advanced hepatocellular carcinoma: A phase Ib clinical trial.

Final clinical outcome and biomarker analysis of sintilimab plus a bevacizumab biosimilar (IBI305) for advanced hepatocellular carcinoma: A phase Ib clinical trial.

Abstract Poster

Authors

null

Wen Zhang

Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Wen Zhang , Caifeng Gong , Xinyu Bi , Peng Xuenan , Yongkun SUN , Yan Wang , Hui Zhou , Hong Zhao , Jianqiang Cai , Ai-Ping Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04072679.

DOI

10.1200/JCO.2022.40.4_suppl.455

Abstract #

455

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Leijuan Gan

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.

Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.

First Author: Alina Pascale

First Author: Ming Liu

First Author: Yiqun Du